drugset / Trial / NCT05676931
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
RandomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.
Timeline
- Start
- 2023-02-21
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | Intravenous |
| Subject | Domvanalimab | Monoclonal antibody | — | Intravenous |
| Subject | Quemliclustat | Small molecule | — | Intravenous |
| Subject | Zimberelimab | Monoclonal antibody | — | Intravenous |